Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

<p class="first" id="d8775108e182">Two phase 3 trials with identical design, LIBERTY AD SOLO 1 (NCT02277743) and LIBERTY AD SOLO 2 (NCT02277769), confirmed dupilumab efficacy and safety versus placebo in adults with moderate-to-severe atopic dermatitis (AD). </p>

Related collections

Author and article information

Journal

Title: Journal of Dermatological Science

Abbreviated Title: Journal of Dermatological Science

Publisher: Elsevier BV

ISSN (Print): 09231811

Publication date Created: May 2019

Publication date (Print): May 2019

Volume: 94

Issue: 2

Pages: 266-275

Article

DOI: 10.1016/j.jdermsci.2019.02.002

PubMed ID: 31109652

SO-VID: 465022ce-474d-4e7c-986e-fbb8e40c33df

License:

https://www.elsevier.com/tdm/userlicense/1.0/

http://creativecommons.org/licenses/by-nc-nd/4.0/

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 70

See all cited by